151751-Najiba-Chargi

428 CHAPTER 21 sarcopenia in older patients based on the presence of bot low muscle mass and low muscle function (strength or performance). 12 This study investigated the prognostic impact of low skeletal muscle mass, low muscle function and the prognostic impact of both low skeletal muscle mass and muscle function for survival. Of the 85 patients, 48.2% had both lowmuscle mass and muscle function. Solely, low skeletal muscle mass or lowmuscle function were not prognostic for overall survival. However, patients with both low skeletal muscle mass and lowmuscle function (sarcopenia definition by EWGSOP) had a significantly decreased overall survival compared to patients without sarcopenia (12.07 months versus 13.60 months, HR 2.80, p<0.05). The 3-years overall survival was significantly shorter for elderly with sarcope - nia compared to elderly patients without sarcopenia (39% versus 75%, p<0.05). Chapter 19 presents a study performed in 150 elderly head and neck cancer patients (≥60 years). Elderly patients are both at risk for having sarcopenia as well as frailty. Both are associated with ad - verse outcomes. As previously mentioned, sarcopenia in elderly is measured by both skeletal muscle mass and muscle function (strength or function). Frailty is screened with use of the G8 frailty questionnaire and diagnosed by a time-consuming comprehensive geriatric assess - ment (CGA). 13 This study was performed to investigate whether sarcopenia may be a marker for frailty. Frail patients were significantly more likely to be sarcopenic ( χ 2  = 4.88, p<0.05). Multivariate regression analysis showed that significant predictors were comorbidity score (OR 5.5, p<0.01) and skeletal muscle mass index (OR 0.9, p<0.01) for frailty and age (OR 3.7, p<0.05) and G8 frailty score (OR 3.7, p<0.05) for sarcopenia. Therefore, assessment of skeletal muscle mass may be used as an alternative screening tool for the G8 questionnaire for frailty screening, i.e., selection of patients who need a time-consuming CGA. Chapter 20 presents a study performed in 73 elderly head and neck cancer patients (≥70-years) to investigate the association between sarcopenia (lowmusclemass andmuscle function) and a comprehensive geriatric assessment (CGA). Frail patients diagnosed by CGA were more likely to have a low SMI and to be sarcopenic at diagnosis. Multivariate regression analysis with frailty diagnosed by CGA as dependent variable distinguished skeletal muscle mass index as a significant predictor of frailty (OR 0.89, p<0.05). Lowmuscle mass, based on SMI, may be able to predict some CGA domain outcomes in older patients with head and neck cancer and is easier to use then a CGA. These findings should ideally be validated in a larger, prospective cohort study.